Stockreport

Erasca (ERAS) Climbs 390% YTD on ‘Best-in-Class' Potential of Cancer Treatment [Yahoo! Finance]

Erasca, Inc.  (ERAS) 
PDF Erasca has seen its share prices soar by 390 percent year-to-date, as investors sought to increase their exposure in the company amid developments on its treatment cand [Read more]